

REMARKS

Applicants have amended claims 1-13 to obviate issues raised by the Examiner in the rejection thereof under 35 U.S.C. §112, Second Paragraph and to correct formatting items. Support for the amendments can be found throughout the specification, e.g., alkyl at page 4, lines 4-6, cycloalkyl at page 4, lines 9-10, pharmaceutically acceptable salts at page 16, lines 25-26, pharmaceutically compatible at page 19, line 13, and appropriate dosage at page 21, lines 11-12.

Applicants have canceled claim 14 to obviate the rejection therewith. Applicants reserve the right to pursue claims to the subject matter of canceled claim 14.

Applicants added new claim 15. Support for this claim is found throughout the specification, e.g., specification at page 17, lines 9-13, and 17-18, and at page 21, lines 11-12.

Applicants submit that the present claims do not encompass new matter.

I. Rejection of Claims 1-13 under 35 USC § 112, Second Paragraph

The Examiner rejected Claims 1-13 for the following

(A). Claims 1-9 recite as: "A product of general Formula or Formulae (where applicable) or a product according to the preceding claim". Correction to: "A compound of" and "claim 2 or claim 3" is required

(B). Claims 1-10, 11, 13, 14 recite: "A product" and "or salt thereof". Correction to "A compound" and "pharmaceutically acceptable salt" thereof is required

(C). Claims 1 recites: "Alkyl and cycloalkyl". The claim does not exactly say about the nature, size, and degree of saturation of the groups. Specification on page 4 in lines 1-10 defines these terms. Are branched alkyls and saturated 5- membered cycloalkyls excluded? Corrections to: "Alkyl consisting of 1 to 6 carbon atoms and cycloalkyl consisting of 5 or more membered saturated cycloalkyl rings" is required.

(D). Claim 10 recites: "chemical formula of a compound". Correction to: "A compound of claim 1" is required.

(E). Claims 13 recites: "A medicament comprising as active principal a product according to claim 1 and an excipient". Correction to: "A pharmaceutical composition A compound according to claim 1 and an pharmaceutically acceptable excipient" is required.

Paper No. 8 at page 3.

Applicants traverse the rejection.

Applicants submit that the amendment of claims as noted above renders moot the present rejection of claims 1-13 under 35 USC § 112, Second Paragraph. Consequently, Applicants request the reconsideration and withdrawal of the rejection.

II. Rejection of Claim 14 under 35 USC §§ 101 and 112, First Paragraph


Applicants submit that the rejection of claim 14 under 35 USC §§ 101 and 112, First Paragraph has been rendered moot in view of the claim being canceled. Consequently, Applicants request the reconsideration and withdrawal of the rejection.

In light of the above amendments and remarks, it is respectfully submitted that the present application is in condition for allowance. Early notice to this effect is, thus, respectfully requested.

Respectfully submitted,

May 20, 2004

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-5674
Telefax (908) 231-2626


Raymond S. Parker, III, Ph.D., Reg. No. 34,893
Attorney/Agent for Applicant

Aventis Docket No. ST99001 US CNT